Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience
| العنوان: | Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience |
|---|---|
| المؤلفون: | Uma H. Athale, Jeffrey E. Rubnitz, Laura C. Bowman, Deo Kumar Srivastava, Xin Tong, David R. Head, Frederick G. Behm, Raul C. Ribeiro, Ching-Hon Pui, Bassem I. Razzouk, Susana C. Raimondi |
| المصدر: | Blood. 97:3727-3732 |
| بيانات النشر: | American Society of Hematology, 2001. |
| سنة النشر: | 2001 |
| مصطلحات موضوعية: | Male, Down syndrome, medicine.medical_specialty, Subsequent Relapse, Immunology, Biochemistry, Disease-Free Survival, Acute megakaryoblastic leukemia, Leukemia, Megakaryoblastic, Acute, Internal medicine, medicine, Humans, Transplantation, Homologous, Prospective Studies, Survival rate, Bone Marrow Transplantation, Retrospective Studies, Childhood Acute Megakaryoblastic Leukemia, business.industry, Remission Induction, Myeloid leukemia, Neoplasms, Second Primary, Cell Biology, Hematology, Prognosis, medicine.disease, Surgery, Survival Rate, Transplantation, Leukemia, Treatment Outcome, Female, Down Syndrome, business |
| الوصف: | To describe the clinical and biologic features of pediatric acute megakaryoblastic leukemia (AMKL) and to identify prognostic factors, experience at St Jude Children's Research Hospital was reviewed. Of 281 patients with acute myeloid leukemia treated over a 14-year period, 41 (14.6%) had a diagnosis of AMKL. Six patients had Down syndrome and AMKL, 6 had secondary AMKL, and 29 had de novo AMKL. The median age of the 22 boys and 19 girls was 23.9 months (range, 6.7-208.9 months). The rate of remission induction was 60.5%, with a 48% rate of subsequent relapse. Patients with Down syndrome had a significantly higher 2-year event-free survival (EFS) estimate (83%) than did other patients with de novo AMKL (14%) or with secondary AMKL (20%; P < or =.038). Among patients who had de novo AMKL without Down syndrome, 2-year EFS was significantly higher after allogeneic bone marrow transplantation (26%) than after chemotherapy alone (0%; P =.019) and significantly higher when performed during remission (46%) than when performed during persistent disease (0%; P =.019). The 5-year survival estimates were significantly lower for de novo AMKL (10%) than for other forms of de novo AML (42%; P |
| تدمد: | 1528-0020 0006-4971 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9b6a2c35f5ae9a128f77fdc0f1586edTest https://doi.org/10.1182/blood.v97.12.3727Test |
| رقم الانضمام: | edsair.doi.dedup.....b9b6a2c35f5ae9a128f77fdc0f1586ed |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15280020 00064971 |
|---|